Disrupting key structure in TB bacterium could aid in new drug designPublished On: Wed, May 12th, 2010 | Proteomics | By BioNews
In a bid to find new ways to fight tuberculosis (TB), scientists have found that disabling a structure essential to the bacterium’s survival could kill the microbes in the infected host and thwart TB infections.
In a study, scientists from the U.S. Department of Energy”s (DOE) Brookhaven National Laboratory, Stony Brook University (SBU), and Weill Cornell Medical College describe new features of how this structure, known as a proteasome, is put together and how it works.
The details could assist researchers working to develop anti-TB drugs.
“Mycobacterium tuberculosis, the bacterium that causes TB, infects one person in three worldwide, so finding new ways to battle this pathogen is a major public health priority —particularly in developing nations where active TB infections are endemic,” said study co-author Huilin Li.
Earlier studies revealed important structural details of the Mycobacterium tuberculosis proteasome, a piece of cellular machinery that carves up unwanted or damaged proteins, allowing the bacterium to evade a key defense of the human immune system.
The researchers have even identified small molecules that might be incorporated into drugs to inhibit the proteasome.
“The primary aim of this new study was to look at how the proteasome, comprised of 28 proteins, is constructed,” said Li.
The scientists used Brookhaven Lab’s National Synchrotron Light Source (NSLS) — a source of intense x-ray, ultraviolet, and infrared light — and a cryo-electron microscope to take molecular-level snapshots of the proteasome at various stages of assembly.
The studies revealed important intermediate steps and changes in the shapes of the components making up the completed structure.
The snapshots also reveal how one component in particular can inhibit the assembly process.
“Such detailed understanding of the assembly process might suggest novel approaches for developing anti-TB drugs by preventing the maturation of the proteasome. This would be an alternative to the traditional approach of inhibiting the activity of the mature proteasome,” said Li.
The researchers were also curious to find out how the Mycobacterium tuberculosis proteasome keeps the entrance to the protein-cleaving chamber shut.
“The fully constructed proteasome is literally a death chamber for cellular proteins, so the passage to the chamber has to be safely closed, and open only when necessary,” explained Li.
Higher-level organisms, such as humans or yeast, also have gate-closed proteasomes to degrade unwanted proteins. In these cases, the gate closure mechanism is known and straightforward—each of the seven end proteins is different, and they can assume different conformations, or shapes, to open and close the gate.
But in bacterial proteasomes, the seven end proteins are identical.
“The question has been how the same protein sequence takes on the necessarily different conformations in order to seal the central pore,” said Li.
Images taken by the scientists using x-ray beams at the NSLS reveal an asymmetric and tightly closed gate structure at the seven-fold symmetrical entrance.
The scientists also snapped additional images showing that the gate structure retains some flexibility.
“This flexibility may be key to opening the gate to allow entry to proteins that need to be degraded. Figuring out how to reduce the flexibility, and thus keep the gate permanently shut, could be yet another strategy in developing proteasome-targeting anti-TB drugs,” said Li.
The new approaches are particularly attractive because the differences in assembly and gating mechanisms between human and TB proteasomes are more significant than the differences in the enzyme active sites that have been primary targets for drug development.
Thus, drugs designed to inactivate these aspects of the TB proteasome would be less likely to also inhibit proteasomes in human cells.
The study appeared online in EMBO J, the journal of the European Molecular Biology Organization.